Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6% – Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 3.6% during trading on Tuesday . The company traded as low as $6.45 and last traded at $6.50. 5,126,260 shares traded hands during trading, a decline of 65% from the average session volume of 14,725,752 shares. The stock had previously closed at $6.74.

Analyst Ratings Changes

RXRX has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Price Performance

The company has a market cap of $2.47 billion, a price-to-earnings ratio of -4.13 and a beta of 0.85. The company’s 50 day moving average price is $6.94 and its 200-day moving average price is $6.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.43) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,894 shares of company stock valued at $317,139 over the last ninety days. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the third quarter valued at $25,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares during the last quarter. Amalgamated Bank raised its position in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, KBC Group NV lifted its stake in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.